Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003093 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy in Treating Children With Neuroblastoma
A Phase 3 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 573
- Enrollment target
NCT00003093 is a Phase 3 study that has completed, run by Children's Oncology Group. The registered enrollment target is 573 participants.
The verdict
NCT00003093, a Phase 3 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 573 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Combination chemotherapy plus surgery may be an effective treatment for neuroblastoma. PURPOSE: This phase III trial is studying how well combination chemotherapy followed by surgery works in treating young patients with neuroblastoma.
Interventions
- DRUG carboplatin
- DRUG cyclophosphamide
- BIOLOGICAL filgrastim
- DRUG doxorubicin hydrochloride
- BIOLOGICAL sargramostim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 573 participants |
| Start Date | 1988-03 |
| Est. Completion | 2011-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003093
The ClinicalTrials.gov registry entry for NCT00003093 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 573 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which carboplatin is the first listed.
NCT00003093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003093 about?
NCT00003093 is a clinical study titled "Combination Chemotherapy in Treating Children With Neuroblastoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Combination chemotherapy plus surgery may be an effective treatment for neuroblastoma. PURPOSE: This phase III trial is stu...
What is the current status of trial NCT00003093?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 573 participants. The study started on 1988-03. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00003093?
The interventions under investigation include: carboplatin (DRUG), cyclophosphamide (DRUG), filgrastim (BIOLOGICAL), doxorubicin hydrochloride (DRUG), sargramostim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003093?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.